Viral Load

• 

  Subject Areas on Research

  • 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. 
  • A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. 
  • A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. 
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. 
  • A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. 
  • A phase I/II study of the protease inhibitor indinavir in children with HIV infection. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. 
  • A randomized controlled trial of health information exchange between human immunodeficiency virus institutions. 
  • A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. 
  • A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. 
  • A vital role for interleukin-21 in the control of a chronic viral infection. 
  • A whole-genome association study of major determinants for host control of HIV-1. 
  • Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. 
  • Acute HIV-1 infection in the Southeastern United States: a cohort study. 
  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • Adjunctive Use of Cidofovir and Intravenous Immunoglobulin to Treat Invasive Adenoviral Disease in Solid Organ Transplant Recipients. 
  • Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials. 
  • An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 
  • An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. 
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. 
  • Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. 
  • Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. 
  • Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo. 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Approach to the treatment-naïve patient with HCV genotype 1 infection. 
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. 
  • Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV. 
  • Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy. 
  • Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. 
  • Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV. 
  • Autoimmune hepatitis in a child with chronic hepatitis B virus infection. 
  • B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. 
  • CCL3L1 and HIV/AIDS susceptibility. 
  • CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. 
  • CSF, plasma viral load and HIV associated dementia. 
  • Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count. 
  • Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. 
  • Changes in Circulating B Cell Subsets Associated with Aging and Acute SIV Infection in Rhesus Macaques. 
  • Changes in HIV Outcomes Following Depression Care in a Resource-Limited Setting: Results from a Pilot Study in Bamenda, Cameroon. 
  • Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 
  • Changes in the etiology, incidence and prognosis of acute lower respiratory track infections in human immunodeficiency virus patients. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. 
  • Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). 
  • Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. 
  • Clinical measles after measles virus challenge in simian immunodeficiency virus-infected measles virus-vaccinated rhesus monkeys. 
  • Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1. 
  • Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region beta repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus-infected children. 
  • Common genetic variation and the control of HIV-1 in humans. 
  • Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. 
  • Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C. 
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. 
  • Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. 
  • Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates. 
  • Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures. 
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. 
  • Construction and characterization of infectious cDNA clones of enterovirus 71 (EV71). 
  • Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. 
  • Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. 
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. 
  • Copy number variation of KIR genes influences HIV-1 control. 
  • Correlates of Self-Reported Viral Suppression Among HIV-Positive, Young, Black Men Who Have Sex With Men Participating in a Randomized Controlled Trial of An Internet-Based HIV Prevention Intervention. 
  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. 
  • Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. 
  • Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. 
  • Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. 
  • Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. 
  • Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. 
  • Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. 
  • DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. 
  • Defining the rural HIV epidemic: correlations of 3 definitions--South Carolina, 2005-2011. 
  • Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Detection of BK polyomavirus after kidney transplantation: a comparison of urine electron microscopy with plasma polymerase chain reaction. 
  • Differential microRNA regulation of HLA-C expression and its association with HIV control. 
  • Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. 
  • Disseminated Adenovirus Infection After Combined Liver-Kidney Transplantation. 
  • Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. 
  • Drivers of Inter-individual Variation in Dengue Viral Load Dynamics. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. 
  • Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. 
  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. 
  • Dynamics of syncytium-inducing and non-syncytium-inducing type 1 human immunodeficiency viruses during primary infection. 
  • Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Editorial comment: renal insufficiency in HIV-infected patients may not always be HIVAN. 
  • Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. 
  • Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. 
  • Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. 
  • Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys. 
  • Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study. 
  • Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. 
  • Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. 
  • Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. 
  • Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. 
  • Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients. 
  • Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. 
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. 
  • Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. 
  • Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. 
  • Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. 
  • Factors associated with failure to list HIV-positive kidney transplant candidates. 
  • Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. 
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. 
  • Focusing HIV prevention on those most likely to transmit the virus. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 
  • Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. 
  • Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. 
  • Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. 
  • HIV and older adults: clinical outcomes in the era of HAART. 
  • HIV antibodies for treatment of HIV infection. 
  • HIV community viral load trends in South Carolina. 
  • HIV heterosexual transmission: a hypothesis about an additional potential determinant. 
  • HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. 
  • HIV-1 dynamics in haemodialysis patients. 
  • HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. 
  • HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. 
  • Hepatitis B virus viral load and treatment decision. 
  • Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. 
  • Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys. 
  • High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. 
  • Human herpesvirus 7 primary infection in kidney transplant recipients. 
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 
  • Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 
  • Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. 
  • Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. 
  • Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. 
  • Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. 
  • Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. 
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immunization against SIVmne in macaques using multigenic DNA vaccines. 
  • Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. 
  • Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. 
  • Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. 
  • Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study. 
  • Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. 
  • Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. 
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. 
  • Infection with GB virus C and reduced mortality among HIV-infected patients. 
  • Inflammasome expression and cytomegalovirus viremia in critically ill patients with sepsis. 
  • Influence of HLA-C expression level on HIV control. 
  • Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 
  • Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. 
  • Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. 
  • Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 
  • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 
  • Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 
  • Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. 
  • Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees. 
  • Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. 
  • Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys. 
  • Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. 
  • Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. 
  • Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection. 
  • Lost in translation? IL28B's discovery and the journey back to the patient. 
  • Low Levels of Physical Activity Among Older Persons Living with HIV/AIDS Are Associated with Poor Physical Function. 
  • Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. 
  • Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. 
  • Memory CD4(+) T lymphocytes in the gastrointestinal tract are a major source of cell-associated simian immunodeficiency virus in chronic nonpathogenic infection of African green monkeys. 
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. 
  • Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South. 
  • Mixed model analysis of censored longitudinal data with flexible random-effects density. 
  • Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Molecular evaluation of BK polyomavirus nephropathy. 
  • Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. 
  • Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. 
  • Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. 
  • Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. 
  • Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. 
  • Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. 
  • Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. 
  • Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. 
  • Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. 
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Oseltamivir resistance during treatment of influenza A (H5N1) infection. 
  • Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. 
  • Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. 
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. 
  • Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States. 
  • Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. 
  • Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. 
  • Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. 
  • Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. 
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. 
  • Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. 
  • Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. 
  • Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. 
  • Physiological and psychosocial factors that predict HIV-related fatigue. 
  • Physiological correlates of HIV-related fatigue. 
  • Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. 
  • Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. 
  • Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 
  • Potent simian immunodeficiency virus-specific cellular immune responses in the breast milk of simian immunodeficiency virus-infected, lactating rhesus monkeys. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictors of glycaemic control among HIV-positive veterans with diabetes. 
  • Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. 
  • Preexposure prophylaxis for HIV infection among African women. 
  • Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. 
  • Preoperative immune status determines anal condyloma recurrence after surgical excision. 
  • Preservation of memory CD4(+) T lymphocytes in breast milk of lactating rhesus monkeys during acute simian immunodeficiency virus infection. 
  • Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection. 
  • Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. 
  • Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. 
  • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • Protection from pathogenic SIV challenge using multigenic DNA vaccines. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. 
  • Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. 
  • Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy. 
  • Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. 
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. 
  • Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. 
  • Recovery of live virus after storage at ambient temperature using ViveST™. 
  • Regular Marijuana Use is Associated with Poor Viral Suppression in HIV-Infected Adolescents and Young Adults. 
  • Relation of lifetime trauma and depressive symptoms to mortality in HIV. 
  • Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 
  • Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. 
  • Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. 
  • Review of the use of hepatitis B core antibody-positive kidney donors. 
  • Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 
  • Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. 
  • Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. 
  • Rural-urban differences in HIV viral loads and progression to AIDS among new HIV cases. 
  • Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. 
  • Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. 
  • Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. 
  • Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. 
  • Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Serum leptin and CD4+ T lymphocytes in HIV+ children during highly active antiretroviral therapy. 
  • Sexual behaviour, condom use, and disclosure of HIV status in HIV infected heterosexual individuals attending an inner London HIV clinic. 
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. 
  • Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. 
  • Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Stemming the tide of hepatitis B virus related hepatocellular carcinoma? 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. 
  • Systematic review of the performance of HIV viral load technologies on plasma samples. 
  • Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. 
  • Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. 
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. 
  • The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi. 
  • The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. 
  • The impact of host immune status on the within-host and population dynamics of antigenic immune escape. 
  • The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services. 
  • The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. 
  • The magnitude and kinetics of the mucosal HIV-specific CD8+ T lymphocyte response and virus RNA load in breast milk. 
  • The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Tollip SNP rs5743899 modulates human airway epithelial responses to rhinovirus infection. 
  • Transcriptional network predicts viral set point during acute HIV-1 infection. 
  • Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. 
  • Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. 
  • Transmitted/founder simian immunodeficiency virus envelope sequences in vesicular stomatitis and Semliki forest virus vector immunized rhesus macaques. 
  • Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. 
  • Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. 
  • Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. 
  • Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. 
  • Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. 
  • Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. 
  • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. 
  • Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. 
  • [Renal transplantation in patients with HIV infection]. 
• 

  Keywords of People

  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • McClain, Micah Thomas, Associate Professor of Medicine, Medicine, Infectious Diseases
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology